The fill-finish market—a traditionally stable one—is increasingly adopting new technologies. Research from our 12th Annual Report and Survey of Biopharmaceutical Manufacturing, and other studies ...

The "Biologics Fill Finish Services Market Industry Trends and Global Forecasts to 2035, by Type of Primary Packaging Container, Type of Biologic Manufactured, Scale of Operation, Therapeutic Area, ...

PCI Pharma, a Philadelphia-based CDMO, will spend $100 million to beef up aseptic liquid fill-finish manufacturing operations at its Bedford, New Hampshire, facility. The project follows PCI’s ...

Dublin, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The "Fill Finish Manufacturing Market by Product ((Consumables (PFS (Glass), Plunger Stopper), Vial (RTU, Polymer), Vial ...

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Biologics Fill Finish Services Market Industry Trends and Global Forecasts to 2035, by Type of Primary Packaging Container, Type of Biologic Manufactured ...

SPOKANE, Wash.--(BUSINESS WIRE)--Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological ...

The MarketWatch News Department was not involved in the creation of this content. DELRAY BEACH, Fla., Aug. 19, 2025 /PRNewswire/ -- The global Fill Finish Manufacturing Market, valued at US$16.85 ...

Fill and finish operations involve filling and sealing products into final-user containers with sterile procedures. These services are most useful for medical-grade products like cartridges, medicinal ...

In a context where reducing time-to-market is key, Stevanato Group’s new EZ-fill® Kit offers fast access to a customizable and versatile solution to pharma and biotech companies needing to efficiently ...

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Fill Finish Pharmaceutical Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Fill Finish Service ...

COPENHAGEN (Reuters) - Novo Nordisk's acquisition of three fill-finish sites will help boost output of its popular Wegovy and Ozempic drugs, the CEO of its parent company Novo Holdings said on Monday.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences ...